Interview with Dieter Torheiden, Managing Director, Solvay Australia
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
Address: 20-22 McPherson St, Banksmeadow 2019, NSW,,Australia
Tel: 61-2-93168000
Web: http://www.solvayinterox.com.au/
Solvay Interox is the world’s leading producer of hydrogen peroxide and its derivatives, with production facilities worldwide. Solvay Interox Pty Ltd in Australia is wholly owned by Solvay and is a member of the worldwide Solvay Group of chemical and pharmaceutical companies. Solvay Interox in Australia is based in Banksmeadow, NSW and serves the peroxygen needs of Australia, New Zealand and the SW Pacific Islands. Solvay Interox’s Quality Management System is registered to the ISO 9002:1994 International Quality Standard for our hydrogen peroxide manufacturing facility and supporting corporate functions. We also actively support the Responsible Care ® initiative as a priority business guideline.
Hydrogen Peroxide
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
Would you please introduce The Pharmacy Guild to our readers, giving an insight in its function and its membership? We are the premium body representing community pharmacies in Australia, about…
Earlier this year the company set a crucial step in its internationalization strategy with the acquisition of Ascent. Would you outline the significance of the acquisition within Watson’s global expansion…
We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities,…
Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike…
You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine,…
In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We…
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
See our Cookie Privacy Policy Here
